comprehensive -WSS

comprehensive

author：comprehensive 2025-10-01 23:43:34 - browse：897

The back of three medicine containers, a bottle in between two boxes, all showing labels — coverage from STAT — Adobe

After a drug enters the market, it’s up to Food and Drug Administration regulators to ensure its continued safety and efficacy. A recent New York Times story suggests that, in the case of the popular asthma drug Singulair, the FDA fell short — both because the agency delayed action for years on reports from patient advocates and independent groups that the drug could cause suicidal thoughts, and because when it did add a warning label about its potential side effects in 2020, clinicians and patients still weren’t always aware of the risks.

Experts say that the Singulair incident highlights a flawed system, both in the U.S. and globally, for monitoring adverse reactions after a drug is on the market — one that will require extensive changes to address.

“The question is, how safe do you want to be?” said Ameet Sarpatwari, the assistant director of the Program on Regulation, Therapeutics, and Law at Brigham and Women’s Hospital. Ideally, he said, the FDA should be able to both stay on top of safety concerns and avoid unnecessarily restricting access to drugs. “Are we at the right balance? I think there are definitely situations for many drugs where you can say, no, we’re not really at the right balance, and the FDA should be taking a more aggressive stance in promoting patient safety.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Why depression after traumatic brain injury is distinct

focus

WSS

Ebola: Gilead Sciences antiviral shows promise as new treatment

Male and female sex labels in research insufficient, scientists say

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Flagship Pioneering startup Sonata Therapeutics lays off 21

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

John Green on his newest strategy for fighting tuberculosis

Wikipedia

comprehensive

focus

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

FDA warns medical device makers about rise in fabricated data

Heart attack and stroke risk calculators need revising

John Green on his newest strategy for fighting tuberculosis

BioMarin wins approval for gene therapy to treat hemophilia A

Weight loss drugs aren’t covered by Obamacare. That may change

Hepatitis C has a cure — but many Americans still lack access to it

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Hepatitis C has a cure — but many Americans still lack access to it

Ebola: Gilead Sciences antiviral shows promise as new treatment

leisure time

Why depression after traumatic brain injury is distinct

As AI regulations shape up, health tech startups beg for clarity

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Ebola: Gilead Sciences antiviral shows promise as new treatment

Flagship Pioneering startup Sonata Therapeutics lays off 21

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

focus

focus

focus

entertainment